This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

QIAGEN's CEO Hosts Investor Day - Conference Call Transcript

For those of you who have been in this industry 20 years ago and compare now the rate of innovation of new product introductions to what we’re seeing today, this is truly a completely different, completely more significant rate of innovation that we have seen than we’ve seen ever in the last 20 years. And the technology is disseminating.

So we’re not anymore talking about pathology being confined to very select spaces or molecular testing, in general, but it is going all across the healthcare industry and also into everyday life. So let me talk very briefly how we are positioned in this industry going forward.

In Molecular Diagnostics, we’re today generating about 46% of our sales base. And we are seeing very substantial long-term growth opportunities based on the fact that this technology is revolutionizing clinical care and providing new answers, better answers to the needs in the healthcare industry.

Our customers are typically reference lab from the hospitals, and we have a number of strengths that we are putting special emphasis on. It’s Personalized Healthcare, QIAsymphony, the QuantiFERON technology portfolio, and also the world of prevention and, in particular, HPV testing.

Applied Testing, however small, is a very, very exciting growth driver and is growing at very high double-digit growth rates. We expect this market to continue for many years at high double-digit growth rates, because it is addressing markets that are typically vast in size but, only to a very small degree, penetrated with molecular technologies.

Our customers are forensic labs, industrial customers, government agencies, veterinary centers and so on and so on. And we are continually launching new portfolios in this area as soon as a sub-segment gets critical size, which can be as low as $5 million in sales. We address that market with a portfolio of tests that run on the same instruments that we sell into hospitals and clinical labs or into the pharmaceutical and academic environments.

4 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs